OKYO Pharma LimitedNASDAQ: OKYO

OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company's Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic corneal pain (NCP). Jacob highlighted a significant milestone for the trial: the first patient dosed.

LONDON and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic pain (NCP), an ocular condition associated with pain but without an FDA-approved therapy, is pleased to announce that the first patient has been dosed in the Phase 2 trial of topical ocular OK-101 to treat NCP. The Phase 2 study is designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients. A total of 48 patients are planned to enroll for the study, with NCP disease confirmed via confocal microscopy.

OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at treating neuropathic corneal pain (NCP). The trial comes as part of OKYO's broader efforts to address unmet needs in the billion-dollar inflammatory dry eye disease (DED) market and NCP, an eye condition characterized by severe eye pain and sensitivity with no approved therapies.

OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101's use to treat irritated, burning eyes and blurred vision in patients with dry eye disease (DED) The patent, issued on August 6, is US patent no. 12,053,503 titled “Methods for Treating Symptoms of Dry Eye Disease.

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, August 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company's ordinary shares on NASDAQ at a price of US$1.05 per share. This brings the total shareholding of Mr Cerrone to 9,721,570 shares which is 28.73% of issued share capital.

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman Gabriele Cerrone has a beneficial interest, has purchased 35,000 shares of the company at $1 each. The company said the purchase brings Cerrone's total shareholding to 9,671,570 shares, or 28.58% of issued share capital.

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.

OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs and Methods of Use, it covers OK-101 chemerin analogs, strengthening the drug developer's intellectual property in ocular inflammatory and pain conditions.